executive team
Marc Schegerin, MD, MBA
Chief Financial Officer and Chief Operating Officer
Marc Schegerin, MD, MBA, is the Chief Financial Officer and Chief Operating Officer of Morphic. Dr. Schegerin’s responsibilities include Finance (including IR, Treasury, IT, and HR), Business Development and Corporate Strategy and Portfolio Management. Dr. Schegerin also serves as a member of the Board of Directors of SQZ Biotech, a publicly traded company developing cell therapies for cancer and other diseases. Most recently, Dr. Schegerin served as chief financial officer, treasurer and head of strategy & communications at ArQule, an oncology-focused drug developer, until its acquisition by Merck for $2.7bn. Prior to this role, Dr. Schegerin served in various senior healthcare investment banking roles at CitiGroup and Bank of America Merrill Lynch. Dr. Schegerin has also held industry management roles at Biogen and Sage Therapeutics and began his career in the healthcare group at Goldman Sachs. Dr. Schegerin earned his MD from Dartmouth Medical School and MBA from the Tuck School of Business at Dartmouth and undergraduate degrees in premedical studies from Harvard University and finance from Tulane University.
Scroll to Top

Contact Us

Integrin Partnership: Janssen

Morphic entered a research partnership with Janssen in 2019 to discover inhibitors of undisclosed integrin targets. In 2021, this partnership was expanded to include an antibody activator of an integrin target, extending the application of Morphic’s knowledge of integrin biology into modalities beyond small molecules. The antibody activator program is the focus of our collaboration with Janssen today.

Undisclosed Targets

Morphic is leveraging the MInT Platform to discover therapeutically relevant small molecule inhibitors of targets across the integrin family to treat autoimmune diseases, cancer and fibrotic diseases.

Undisclosed Target for Pulmonary Arterial Hypertension

Morphic is deploying the MInT Platform to create small molecule inhibitors of an undisclosed integrin target for evaluation as a potential treatment for pulmonary arterial hypertension (PAH). PAH is a devastating, usually fatal disease characterized by elevated mean pressures in the pulmonary artery and associated with lung and heart dysfunction. Morphic’s PAH program is in preclinical development.


Morphic is developing small molecule inhibitors of the integrin αvβ8 through a combination immuno-oncology approach for the treatment of solid tumors as well as potential additional indications. αvβ8 is known to activate selective isoforms of TGF-β and Morphic has demonstrated that αvβ8 inhibition can potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s αvβ8 inhibitors are in preclinical development.

Next Gen α4β7 Inhibitors

Morphic is developing a family of next generation α4β7 small molecule inhibitors with enhanced attributes using the MInT Platform. These candidates have distinct chemical properties from our first-generation inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles. Morphic’s next generation α4β7 inhibitors are currently in preclinical development.